Lepu Medical(SZ:300003) Cai Jing Wang·2026-01-29 05:45Core Viewpoint - Lepu Medical (300003) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 800 million to 1.2 billion yuan, representing a growth of 223.97% to 385.95% compared to the previous year's net profit of 247 million yuan [1] Financial Performance - The net profit excluding non-recurring gains and losses is also anticipated to be between 800 million to 1.2 billion yuan, which is an increase of 261.29% to 441.93% from the previous year's figure of 221 million yuan [1] - The core business of cardiovascular interventional products shows steady revenue growth, while the pharmaceutical segment has completed inventory clearance in retail channels, achieving double-digit revenue growth [1] Strategic Developments - The company's subsidiary, Minwei Bio, has licensed its proprietary MWN105 injection to Denmark's Sidera, receiving an initial irrevocable investment of 30 million USD as of December 31 [1] - The company has seen positive results from personnel optimization and organizational restructuring, leading to a decrease in both sales and management expenses [1] Challenges - Despite the positive financial outlook, the company experienced a shift from net gains to net losses in foreign exchange due to fluctuations in international currency markets [1] - The company plans to recognize an impairment provision for goodwill [1]